GSK pays up to $230M up front on J&J deal for asthma antibody - FierceBiotech

FierceBiotech

GSK pays up to $230M up front on J&J deal for asthma antibody FierceBiotech GlaxoSmithKline ($GSK) will pay up to £175 million ($230 million) up front to gain global, exclusive rights to a Phase I monoclonal antibody to treat severe asthma from Johnson & Johnson's ($JNJ) Janssen. GSK will assume all activities worldwide once ... GSK in-licenses MAb asthma drug candidate from JanssenThe Pharma Letter (registration) GSK chases next biotech asthma drug with $230 mln J&J dealLondon South East (registration) (blog) all 17 news articles »

from Health - Google News http://news.google.com/news/url?sa=t&fd=R&ct2=us&usg=AFQjCNEnNX-GSFEyLk3NOz6JQHXbj3J0GA&clid=c3a7d30bb8a4878e06b80cf16b898331&cid=52779168519175&ei=VfaYV6jXJMzN3gGzyqjgCg&url=http://www.fiercebiotech.com/biotech/gsk-pays-up-to-230m-upfront-j-j-deal-for-asthma-antibody
via IFTTT